Patents by Inventor Gudrun Vogtentanz
Gudrun Vogtentanz has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240093124Abstract: Disclosed herein is one or more subtilisin variant, nucleic acid encoding same, and compositions and methods related to the production and use thereof, including one or more subtilisin variant that has improved stability and/or soil removal compared to one or more reference subtilisin.Type: ApplicationFiled: April 17, 2023Publication date: March 21, 2024Inventors: Joshua Roy Basler, Michael Stoner, James T. Kellis, Jr., Adam Garske, David Marquez, Katherine Augustyn, Priyanka Chandrasekaran, Miles Christopher Scotcher, Lilia Maria Babe, Richard R. Bott, David A. Estell, Gudrun Vogtentanz, Sina Pricelius, Jian Yao
-
Publication number: 20230383269Abstract: The present invention relates to alpha/beta hydrolase variants with improved properties compared to a parent alpha/beta hydrolase, e.g., having increased temperature stability, methods of using and producing such variants including methods of directing the quaternary structure formation from homo-dimers to homo-tetramers.Type: ApplicationFiled: March 10, 2021Publication date: November 30, 2023Inventors: Andreas HOEBARTNER-GUSSL, Manuela KILLINGER, Gudrun VOGTENTANZ, Sebastian FRUHAUF, Florian KRAINER
-
Publication number: 20230235297Abstract: The present invention relates to a method of converting 3-keto-DON into 3-epi-DON, reducing the content of DON in a composition comprising DON or of reducing the toxicity of a composition comprising DON as well as a method for converting a trichothecene comprising a 3-oxo group into a trichothecene comprising a 3-hydroxy group using one or more polypeptide(s) comprising or consisting of SEQ ID NO. 1 or a sequence having a sequence identity of at least 72.0% to SEQ ID NO. 1. Also envisioned are feed or food additives or feed or food as well as pharmaceutical compositions comprising one or more polypeptide(s) comprising or consisting of a sequence of SEQ ID NO. 1 or a sequence having a sequence identity of at least 72.0% to SEQ ID NO. 1 as well as the manufacture thereof. Encompassed are further polypeptide(s) comprising or consisting of a sequence of SEQ ID NO. 1 or a sequence having a sequence identity of at least 88.5% to SEQ ID NO. 1. Also envisioned are host cells or plants.Type: ApplicationFiled: June 8, 2021Publication date: July 27, 2023Inventors: Bernhard Neumayer, Elisabeth Streit, Barbara Weber, Gudrun Vogtentanz
-
Patent number: 11661567Abstract: Disclosed herein is one or more subtilisin variant, nucleic acid encoding same, and compositions and methods related to the production and use thereof, including one or more subtilisin variant that has improved stability and/or soil removal compared to one or more reference subtilisin.Type: GrantFiled: May 31, 2017Date of Patent: May 30, 2023Assignee: Danisco US Inc.Inventors: David Marquez, Michael Stoner, James T. Kellis, Jr., Adam Garske, Joshua Roy Basler, Katherine Augustyn, Priyanka Chandrasekaran, Miles Christopher Scotcher, Lilia Maria Babe, Richard R. Bott, David A. Estell, Gudrun Vogtentanz, Sina Pricelius, Jian Yao
-
Publication number: 20220372450Abstract: The present invention relates to compositions comprising one or more polypeptide(s) comprising or consisting of a sequence of SEQ ID NO. 1-14 or a sequence having a sequence identity of at least 75% to any one of SEQ ID NO. 1-14 and a carrier as well as uses and methods of these polypeptides.Type: ApplicationFiled: August 28, 2020Publication date: November 24, 2022Inventors: Bernhard Neumayer, Elisabeth Streit, Barbara Weber, Gudrun Vogtentanz
-
Publication number: 20200332229Abstract: Disclosed herein is one or more subtilisin variant, nucleic acid encoding same, and compositions and methods related to the production and use thereof, including one or more subtilisin variant that has improved stability and/or soil removal compared to one or more reference subtilisin.Type: ApplicationFiled: May 31, 2017Publication date: October 22, 2020Applicant: Danisco US Inc.Inventors: David MARQUEZ, Michael STONER, James T. KELLIS, JR., Adam GARSKE, Joshua Roy BASLER, Katherine AUGUSTYN, Priyanka CHANDRASEKARAN, Miles Christopher SCOTCHER, Lilia Maria BABE, Richard R. BOTT, David A. ESTELL, Gudrun VOGTENTANZ, Sina PRICELIUS, Jian YAO
-
Publication number: 20170145396Abstract: The present disclosure is generally directed to enzymes and in particular beta-glucosidase variants. Also described are nucleic acids encoding beta-glucosidase variants, compositions comprising beta-glucosidase variants, methods of using beta-glucosidase variants, and methods of identifying additional useful beta-glucosidase variants.Type: ApplicationFiled: August 29, 2016Publication date: May 25, 2017Applicant: DANISCO US INC.Inventors: Richard R. BOTT, Thijs KAPER, Bradley R. KELEMEN, Frits GOEDEGEBUUR, Ronaldus Wilhelmus Joannes HOMMES, Slavko KRALJ, Paulien KRUITHOF, Igor NIKOLAEV, Wilhelmus Antonious Hendricus VAN DER KLEY, Johannes Franciscus Thomas VAN LIESHOUT, Sander VAN STIGT THANS, Gudrun VOGTENTANZ, Mats SANDGREN
-
Patent number: 9523087Abstract: The present disclosure relates to cellulase variants. In particular the present disclosure relates to cellulase variants having improved expression, activity and/or stability. Also described are nucleic acids encoding the cellulase variants, compositions comprising the cellulase variants, and methods of use thereof.Type: GrantFiled: February 25, 2014Date of Patent: December 20, 2016Assignee: DANISCO US INCInventors: Wolfgang Aehle, Richard R. Bott, Benjamin S. Bower, Jonathan Caspi, David A. Estell, Frits Goedegebuur, Ronaldus Wilhelmus Joannes Hommes, Thijs Kaper, Bradley R. Kelemen, Slavko Kralj, Johannes Franciscus Thomas Van Lieshout, Igor Nikolaev, Sander Van Stigt Thans, Louise Wallace, Gudrun Vogtentanz, Mats Sandgren
-
Patent number: 9447400Abstract: The present disclosure is generally directed to enzymes and in particular beta-glucosidase variants. Also described are nucleic acids encoding beta-glucosidase variants, compositions comprising beta-glucosidase variants, methods of using beta-glucosidase variants, and methods of identifying additional useful beta-glucosidase variants.Type: GrantFiled: November 19, 2010Date of Patent: September 20, 2016Assignee: DANISCO US INC.Inventors: Richard R. Bott, Thijs Kaper, Bradley Kelemen, Frits Goedegebuur, Ronaldus Wilhelmus Hommes, Slavko Kralj, Paulien Kruithof, Igor Nikolaev, Wilhelmus Antonious Hendricus Van Der Kley, Johannes Franciscus Thomas Van Lieshout, Sander Van Stigt Thans, Gudrun Vogtentanz, Mats Sandgren
-
Patent number: 9084734Abstract: The present invention provides peptides and supported peptides for treating various diseases and conditions. In particularly preferred embodiments, the present invention provides compositions and methods for personal care. In some embodiments the present invention provides compositions for use in skin and/or hair care, as well as cosmetic compositions. IN alternative particularly preferred embodiments, the present invention provides peptides and supported peptides for treating diseases of the skin, such as rosacea. In some particularly preferred embodiments, the supported peptides of the present invention are anti-VEGF peptides. In alternative particularly preferred embodiments, the anti-VEGF peptides are expressed on a scaffold protein. In some most preferred embodiments, the scaffold protein comprises BBI.Type: GrantFiled: April 25, 2006Date of Patent: July 21, 2015Assignee: Danisco US Inc.Inventors: Katherine D. Collier, Anthony Day, Hans de Nobel, David A. Estell, Grant C. Ganshaw, Marc Kolkman, Raj Lad, Jeffrey V. Miller, Christopher J. Murray, Scott D. Power, Brian Schmidt, Anita van Kimmenade, Gudrun Vogtentanz
-
Publication number: 20140302585Abstract: The present disclosure relates to cellulase variants. In particular the present disclosure relates to cellulase variants having improved expression, activity and/or stability. Also described are nucleic acids encoding the cellulase variants, compositions comprising the cellulase variants, and methods of use thereof.Type: ApplicationFiled: February 25, 2014Publication date: October 9, 2014Applicant: DANISCO US INC.Inventors: Wolfgang AEHLE, Richard R. BOTT, Benjamin S. BOWER, Jonathan CASPI, David A. ESTELL, Frits GOEDEGEBUUR, Ronaldus Wilhelmus HOMMES, Thijs KAPER, Bradley R. KELEMEN, Slavko KRALJ, Johannes Franciscus Thomas VAN LIESHOUT, Igor NIKOLAEV, Sander VAN STIGT THANS, Louise WALLACE, Gudrun VOGTENTANZ, Mats SANDGREN
-
Patent number: 8679816Abstract: The present disclosure relates to cellulase variants. In particular the present disclosure relates to cellulase variants having improved expression, activity and/or stability. Also described are nucleic acids encoding the cellulase variants, compositions comprising the cellulase variants, and methods of use thereof.Type: GrantFiled: June 3, 2010Date of Patent: March 25, 2014Assignee: Danisco US Inc.Inventors: Wolfgang Aehle, Richard R. Bott, Benjamin Bower, Jonathan Caspi, David A. Estell, Frits Goedegebuur, Ronaldus W. J. Hommes, Thijs Kaper, Bradley Kelemen, Slavko Kralj, Johan Van Lieshout, Igor Nikolaev, Sander Van Stigt Thans, Louise Wallace, Gudrun Vogtentanz, Mats Sandgren
-
Patent number: 8394941Abstract: The present invention relates to modified variant Bowman Birk Protease Inhibitor proteins (BBPIs) that comprise peptides that bind target proteins, and that are further modified to have greater protease inhibitory activity and/or be produced at greater yields than the unmodified BBPIs. The invention encompasses polynucleotide constructs and expression vectors containing polynucleotide sequences that encode the modified variant BBPIs, the transformed host cells that express and produce the modified variant BBPIs, the modified variant BBPI proteins, the compositions comprising the modified variant BBPIs, and the methods for making and using the modified variant BBPIs in personal care.Type: GrantFiled: April 8, 2011Date of Patent: March 12, 2013Assignee: Danisco US Inc.Inventors: Neelam S. Amin, Katherine D. Collier, Melodie Estabrook, David A. Estell, Bryan P. Fox, Scott D. Power, Brian F. Schmidt, Gudrun Vogtentanz
-
Publication number: 20120135500Abstract: The present disclosure relates to cellulase variants. In particular the present disclosure relates to cellulase variants having improved expression, activity and/or stability. Also described are nucleic acids encoding the cellulase variants, compositions comprising the cellulase variants, and methods of use thereof.Type: ApplicationFiled: June 3, 2010Publication date: May 31, 2012Applicant: Danisco US Inc.Inventors: Wolfgang Aehle, Richard R. Bott, Benjamin Bower, Jonathan Caspi, David A. Estell, Frits Goedegebuur, Ronaldus W.J. Hommes, Thijs Kaper, Bradley Kelemen, Slavko Kralj, Johan Van Lieshout, Igor Nikolaev, Sander Van Stigt Thans, Louise Wallace, Gudrun Vogtentanz, Mats Sandgren
-
Publication number: 20120014885Abstract: The present invention provides peptides and supported peptides for treating various diseases and conditions. In particularly preferred embodiments, the present invention provides compositions and methods for personal care. In some embodiments, the present invention provides compositions for use in skin and/or hair care, as well as cosmetic compositions. In alternative particularly preferred embodiments, the present invention provides peptides and supported peptides for treating diseases of the skin, such as rosacea. In some particularly preferred embodiments, the supported peptides of the present invention are anti-VEGF peptides. In alternative particularly preferred embodiments, the anti-VEGF peptides are expressed on a scaffold protein. In some most preferred embodiments, the scaffold protein comprises BBI.Type: ApplicationFiled: April 25, 2006Publication date: January 19, 2012Inventors: Katherine D. Collier, Anthony Day, Hans de Nobel, David A. Estell, Grant C. Ganshaw, Marc Kolkman, Raj Lad, Jeffrey V. Miller, Christopher J. Murray, Scott D. Power, Brian Schmidt, Anita Van Kimmenade, Gudrun Vogtentanz
-
Publication number: 20110256608Abstract: The present invention relates to modified variant Bowman Birk Protease Inhibitor proteins (BBPIs) that comprise peptides that bind target proteins, and that are further modified to have greater protease inhibitory activity and/or be produced at greater yields than the unmodified BBPIs. The invention encompasses polynucleotide constructs and expression vectors containing polynucleotide sequences that encode the modified variant BBPIs, the transformed host cells that express and produce the modified variant BBPIs, the modified variant BBPI proteins, the compositions comprising the modified variant BBPIs, and the methods for making and using the modified variant BBPIs in personal care.Type: ApplicationFiled: April 8, 2011Publication date: October 20, 2011Applicant: Danisco US Inc.Inventors: Neelam S. Amin, Katherine D. Collier, Melodie Estabrook, David A. Estell, Bryan P. Fox, Scott D. Power, Brian F. Schmidt, Gudrun Vogtentanz
-
Patent number: 7947475Abstract: The present invention relates to modified variant Bowman Birk Protease Inhibitor proteins (BBPIs) that comprise peptides that bind target proteins, and that are further modified to have greater protease inhibitory activity and/or be produced at greater yields than the unmodified BBPIs. The invention encompasses polynucleotide constructs and expression vectors containing polynucleotide sequences that encode the modified variant BBPIs, the transformed host cells that express and produce the modified variant BBPIs, the modified variant BBPI proteins, the compositions comprising the modified variant BBPIs, and the methods for making and using the modified variant BBPIs in personal care.Type: GrantFiled: May 13, 2010Date of Patent: May 24, 2011Assignee: Danisco US Inc.Inventors: Neelam S. Amin, Katherine D. Collier, Melodie Estabrook, David A. Estell, Bryan P. Fox, Scott D. Power, Brian F. Schmidt, Gudrun Vogtentanz
-
Patent number: 7803902Abstract: The present invention relates to modified variant Bowman Birk Protease Inhibitor proteins (BBPIs) that comprise peptides that bind target proteins, and that are further modified to have greater protease inhibitory activity and/or be produced at greater yields than the unmodified BBPIs. The invention encompasses polynucleotide constructs and expression vectors containing polynucleotide sequences that encode the modified variant BBPIs, the transformed host cells that express and produce the modified variant BBPIs, the modified variant BBPI proteins, the compositions comprising the modified variant BBPIs, and the methods for making and using the modified variant BBPIs in personal care.Type: GrantFiled: October 15, 2008Date of Patent: September 28, 2010Assignee: Danisco US Inc.Inventors: Neelam S. Amin, Katherine D. Collier, Melodie Estabrook, David A. Estell, Bryan P. Fox, Scott D. Power, Brian F. Schmidt, Gudrun Vogtentanz
-
Publication number: 20100221780Abstract: The present invention relates to modified variant Bowman Birk Protease Inhibitor proteins (BBPIs) that comprise peptides that bind target proteins, and that are further modified to have greater protease inhibitory activity and/or be produced at greater yields than the unmodified BBPIs. The invention encompasses polynucleotide constructs and expression vectors containing polynucleotide sequences that encode the modified variant BBPIs, the transformed host cells that express and produce the modified variant BBPIs, the modified variant BBPI proteins, the compositions comprising the modified variant BBPIs, and the methods for making and using the modified variant BBPIs in personal care.Type: ApplicationFiled: May 13, 2010Publication date: September 2, 2010Applicant: DANISCO US INC.Inventors: Neelam S. Amin, Katherine D. Collier, Melodie Estabrook, David A. Estell, Bryan P. Fox, Scott D. Power, Brian F. Schmidt, Gudrun Vogtentanz
-
Patent number: 7772181Abstract: The present invention relates to compositions that comprise modified variant Bowman Birk Protease Inhibitor proteins (BBPIs). The modified variant BBPIs comprise peptides that bind target proteins, and that are further modified to have greater protease inhibitory activity and/or be produced at greater yields than the unmodified BBPIs. The invention encompasses the compositions comprising the modified variant BBPIs, and the methods for making and using the compositions in personal care.Type: GrantFiled: October 15, 2008Date of Patent: August 10, 2010Assignee: Danisco US Inc.Inventors: Neelam S. Amin, Katherine D. Collier, Melodie Estabrook, David A. Estell, Bryan P. Fox, Scott D. Power, Brian F. Schmidt, Gudrun Vogtentanz